Lenvatinib and tislelizumab for advanced liver cancer with hepatitis B
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two drugs—lenvatinib (a targeted therapy that blocks blood vessel growth) and tislelizumab (an immunotherapy that helps your immune system fight cancer)—in people with advanced liver cancer who also have hepatitis B. The goal is to see if this combination can shrink tumors or slow the cancer's growth, and to find biomarkers (clues in your blood or tissue) that predict who will benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You need to have hepatitis B (test positive for the surface antigen or certain antibodies).
- You have not had any prior whole-body (systemic) treatment for liver cancer, like chemotherapy, targeted pills, or immunotherapy.
- Your cancer is either locally advanced (cannot be removed by surgery) or has spread to other parts of the body.
- You are in generally good health (able to care for yourself, with a score of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale).
- Your liver function must be good (child-Pugh score of A or mild B, no history of hepatic encephalopathy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
This trial tests a special type of immune cell therapy (called HBV-TCR T cells) that is designed to attack liver cancer cells that carry the hepatitis B virus. It may be given alone or combined with a pill called lenvatinib to see if it can shrink tumors and help people with advanced liver cancer.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This study tests a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), lenvatinib (a targeted therapy pill), and tislelizumab (an immunotherapy)—for people with liver cancer that has spread into the bile ducts and can't be removed by surgery. The goal is to see if this triple therapy helps shrink or control the cancer.
This trial tests adding lenvatinib (a targeted therapy pill) to a combination of two immunotherapy drugs (durvalumab and tremelimumab) for people with liver cancer that cannot be removed by surgery. The goal is to see if the three-drug approach works better than the two immunotherapy drugs alone.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.